RECRUITING Not applicable ClinicalTrials.gov

Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma

Sponsor: Universitätsklinikum Hamburg-Eppendorf • ClinicalTrials.gov ID: NCT06175845

Registry updated: 2026-09-09

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting. The main questions it aims to answer are: * Does radiofrequency ablation of tumorous bile duct occlusion reduce risk of complications in these patients (eg stent dysfunction, delay of chemotherapy, infections etc)? * Is radiofrequency ablation safe in these patients? All participants will receive standard treatment with systemic chemotherapy and bile duct stenting. Researchers will compare two groups (one group will receive additional radiofrequency ablation, the other not).

Interventions

Intraductal biliary radiofrequency ablation (Procedure)
Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction

Eligibility criteria

Inclusion Criteria: 1. Unresectable perihilar and/or ductal CCA with bile duct stenting and palliative systemic therapy as indicated by the local Multidisciplinary Team (MDT) 2. Written informed consent 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 4. Age ≥18 years 5. Eligibility for palliative systemic therapy based on clinical and laboratory parameters (except hyperbilirubinemia) as determined by the local MDT 6. No prior radiofrequency ablation (RFA) for CCA 7. No repeated bile duct stenting in the past 3 months (trial inclusion is possible upon first stent replacement or initial stent placement within past 3 months) 8. No concomitant disease or malignancy interfering with the study procedure or efficacy outcome measures, particularly no severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, myocardial infarction within ≤3 months, significant arrhythmias) and no psychiatric disorders precluding understanding of information of trial related topics and giving informed consent

Conditions

Cholangiocarcinoma Klatskin Tumor Bile Duct Cancer Liver Cancer

Locations

Charite — Berlin, Germany
University Medical Center — Bonn, Germany
Clinic Chemnitz — Chemnitz, Germany
University Clinic — Essen, Germany
University Medical Center Hamburg-Eppendorf — Hamburg, Germany
Medical School Hannover — Hanover, Germany
University Clinic — Heidelberg, Germany
UKSH — Lübeck, Germany
Clinic Ulm — Ulm, Germany

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment